EXELIXIS , immer weiter gehts Richtung Norden - 500 Beiträge pro Seite
eröffnet am 23.06.04 12:33:37 von
neuester Beitrag 24.11.05 16:39:36 von
neuester Beitrag 24.11.05 16:39:36 von
Beiträge: 25
ID: 873.093
ID: 873.093
Aufrufe heute: 1
Gesamt: 2.424
Gesamt: 2.424
Aktive User: 0
ISIN: US30161Q1040 · WKN: 936718 · Symbol: EXEL
22,315
USD
-0,78 %
-0,175 USD
Letzter Kurs 21:12:40 Nasdaq
Neuigkeiten
16.04.24 · Business Wire (engl.)  |
01.04.24 · wO Chartvergleich |
29.03.24 · wO Chartvergleich |
28.03.24 · wO Chartvergleich |
27.02.24 · Business Wire (engl.) |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3.000,00 | +74.900,00 | |
| 2,4700 | +33,51 | |
| 1,5500 | +26,53 | |
| 11,860 | +17,89 | |
| 3,4600 | +17,69 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8501 | -17,47 | |
| 0,8649 | -20,65 | |
| 5,0550 | -22,71 | |
| 4,8200 | -26,30 | |
| 0,6021 | -35,26 |
Feedback
Exelixis Initiates Phase 3 Clinical Trial of XL119 in Bile Duct Cancer
via COMTEX
June 23, 2004
SOUTH SAN FRANCISCO, Calif., Jun 23, 2004 /PRNewswire-FirstCall via COMTEX/ --
Exelixis, Inc. (Nasdaq: EXEL) announced the initiation of the Phase 3 clinical trial of XL119 (becatecarin) as a potential treatment for patients with bile duct cancer. The Phase 3 trial will include approximately 60 centers in the United States, Canada and Europe and is designed to enroll up to 600 patients with inoperable bile duct tumors. The primary endpoint of the trial is survival, and the two-arm trial is designed to compare patients treated with XL119 to patients treated with 5-FU/leucovorin.
"The initiation of the Phase 3 trial of XL119 in bile duct cancer is an important milestone for Exelixis," said George A. Scangos, Ph.D., president and chief executive officer. "For the patients and families who are affected by bile duct cancer, and for whom there are no approved therapies, we are hopeful that XL119 may provide some benefit. We are gratified by the enthusiasm and commitment of clinical investigators in North America and in Europe to this clinical program. We intend to work closely with Covance, our drug development services coordinator, to conduct the Phase 3 clinical trial in a high quality and expeditious manner. We are also appreciative of the National Cancer Institute`s interest in continuing to explore the utility of XL119 in other indications, as encouraging results from these independent exploratory trials could suggest further development activities that Exelixis could undertake for the compound."
Data presented at the 2003 annual meeting of the American Society of Clinical Oncology (ASCO) from the Phase 2 clinical trial of XL119 showed that patients with bile duct tumors (gall bladder tumors and cholangiocarcinomas) treated with XL119 showed encouraging results relative to overall survival and progression free survival (alive without progressive disease, i.e., patients with partial response or stable disease). The safety profile of the compound was manageable and was consistent with that previously observed in Phase 1 and 2 studies. At this meeting, data were also presented showing a survival benefit in patients with non-small cell lung cancer. Data presented at the 2004 ASCO meeting showed additional encouraging results from a Phase 2 trial in patients with refractory breast cancer. Taken together, these findings suggest that XL119 is an active anticancer agent that warrants further clinical study to assess its therapeutic benefit.
In March 2004, Exelixis was granted orphan drug designation for XL119 in bile duct cancer. Orphan drug status is granted to treatments for diseases that affect fewer than 200,000 people in the U.S. and provides the benefits of extended market exclusivity for seven years, tax credits of up to 50% of the qualified clinical trial expenses and a waiver of FDA user fees. The company may also consider applying for European orphan drug designation for XL119 following the commencement of the Phase 3 clinical trial in Europe. Based on market research, Exelixis estimates that the annual incidence of bile duct tumors in currently addressable markets is approximately 30,000 patients.
Exelixis, Inc. is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis` development pipeline includes: XL119, which has entered a Phase 3 clinical trial as a potential treatment for bile duct tumors; XL784, a compound that has completed a Phase 1 clinical trial; XL647, an anticancer compound that has entered a Phase 1 clinical trial; XL999, XL844, XL820 and XL880, anticancer compounds that are potential IND candidates; and multiple other compounds in preclinical development. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline and Bristol-Myers Squibb Company. Under the terms of our research and development collaboration with GlaxoSmithKline, established in October 2002, after completion of proof-of-concept clinical trials, GlaxoSmithKline has the right to elect to develop a limited number of the compounds in our clinical and preclinical pipeline, other than XL119, thus potentially triggering milestone payments and royalties from GlaxoSmithKline. Exelixis has co-promotion rights with GlaxoSmithKline for compounds commercialized under the collaboration. The company has also established agricultural research collaborations with Bayer CropScience, Dow AgroSciences and Renessen LLC. Other partners include Merck & Co., Inc., Schering-Plough Research Institute, Inc., Cytokinetics, Inc., Elan Pharmaceuticals, Inc. and Scios Inc. For more information, please visit the company`s web site at www.exelixis.com.
This press release contains forward-looking statements, including without limitation all statements related to the expected structure of the Phase 3 clinical trial of XL119 and the therapeutic and commercial potential of XL119, XL784, XL647, XL999, XL844, XL820 and XL880 and other compounds in Exelixis` preclinical pipeline. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "slated," "goal" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis` current expectations. Forward-looking statements involve risks and uncertainties. Exelixis` actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the ability of the company to complete the planned Phase 3 clinical trial of XL119; the uncertainty of the clinical trials process and whether the company`s product candidates, including XL119, will demonstrate safety and efficacy; and uncertainty regarding the ability of the company to enroll patients in a timely manner. These and other risk factors are discussed under "Risk Factors" and elsewhere in our quarterly report on Form 10-Q for the quarter ended March 31, 2004 and other filings with the Securities and Exchange Commission. The company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company`s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
NOTE: Exelixis and the Exelixis logo are registered U.S. trademarks. Spectrum selective kinase inhibitor is a trademark of Exelixis, Inc.
SOURCE Exelixis, Inc.
Jane M. Green, Ph.D., VP, Corporate Communications of Exelixis, Inc., +1-650-837-7579, or jmgreen@exelixis.com
http://www.exelixis.com
Copyright (C) 2004 PR Newswire. All rights reserved.
JS200
via COMTEX
June 23, 2004
SOUTH SAN FRANCISCO, Calif., Jun 23, 2004 /PRNewswire-FirstCall via COMTEX/ --
Exelixis, Inc. (Nasdaq: EXEL) announced the initiation of the Phase 3 clinical trial of XL119 (becatecarin) as a potential treatment for patients with bile duct cancer. The Phase 3 trial will include approximately 60 centers in the United States, Canada and Europe and is designed to enroll up to 600 patients with inoperable bile duct tumors. The primary endpoint of the trial is survival, and the two-arm trial is designed to compare patients treated with XL119 to patients treated with 5-FU/leucovorin.
"The initiation of the Phase 3 trial of XL119 in bile duct cancer is an important milestone for Exelixis," said George A. Scangos, Ph.D., president and chief executive officer. "For the patients and families who are affected by bile duct cancer, and for whom there are no approved therapies, we are hopeful that XL119 may provide some benefit. We are gratified by the enthusiasm and commitment of clinical investigators in North America and in Europe to this clinical program. We intend to work closely with Covance, our drug development services coordinator, to conduct the Phase 3 clinical trial in a high quality and expeditious manner. We are also appreciative of the National Cancer Institute`s interest in continuing to explore the utility of XL119 in other indications, as encouraging results from these independent exploratory trials could suggest further development activities that Exelixis could undertake for the compound."
Data presented at the 2003 annual meeting of the American Society of Clinical Oncology (ASCO) from the Phase 2 clinical trial of XL119 showed that patients with bile duct tumors (gall bladder tumors and cholangiocarcinomas) treated with XL119 showed encouraging results relative to overall survival and progression free survival (alive without progressive disease, i.e., patients with partial response or stable disease). The safety profile of the compound was manageable and was consistent with that previously observed in Phase 1 and 2 studies. At this meeting, data were also presented showing a survival benefit in patients with non-small cell lung cancer. Data presented at the 2004 ASCO meeting showed additional encouraging results from a Phase 2 trial in patients with refractory breast cancer. Taken together, these findings suggest that XL119 is an active anticancer agent that warrants further clinical study to assess its therapeutic benefit.
In March 2004, Exelixis was granted orphan drug designation for XL119 in bile duct cancer. Orphan drug status is granted to treatments for diseases that affect fewer than 200,000 people in the U.S. and provides the benefits of extended market exclusivity for seven years, tax credits of up to 50% of the qualified clinical trial expenses and a waiver of FDA user fees. The company may also consider applying for European orphan drug designation for XL119 following the commencement of the Phase 3 clinical trial in Europe. Based on market research, Exelixis estimates that the annual incidence of bile duct tumors in currently addressable markets is approximately 30,000 patients.
Exelixis, Inc. is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis` development pipeline includes: XL119, which has entered a Phase 3 clinical trial as a potential treatment for bile duct tumors; XL784, a compound that has completed a Phase 1 clinical trial; XL647, an anticancer compound that has entered a Phase 1 clinical trial; XL999, XL844, XL820 and XL880, anticancer compounds that are potential IND candidates; and multiple other compounds in preclinical development. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline and Bristol-Myers Squibb Company. Under the terms of our research and development collaboration with GlaxoSmithKline, established in October 2002, after completion of proof-of-concept clinical trials, GlaxoSmithKline has the right to elect to develop a limited number of the compounds in our clinical and preclinical pipeline, other than XL119, thus potentially triggering milestone payments and royalties from GlaxoSmithKline. Exelixis has co-promotion rights with GlaxoSmithKline for compounds commercialized under the collaboration. The company has also established agricultural research collaborations with Bayer CropScience, Dow AgroSciences and Renessen LLC. Other partners include Merck & Co., Inc., Schering-Plough Research Institute, Inc., Cytokinetics, Inc., Elan Pharmaceuticals, Inc. and Scios Inc. For more information, please visit the company`s web site at www.exelixis.com.
This press release contains forward-looking statements, including without limitation all statements related to the expected structure of the Phase 3 clinical trial of XL119 and the therapeutic and commercial potential of XL119, XL784, XL647, XL999, XL844, XL820 and XL880 and other compounds in Exelixis` preclinical pipeline. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "slated," "goal" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis` current expectations. Forward-looking statements involve risks and uncertainties. Exelixis` actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the ability of the company to complete the planned Phase 3 clinical trial of XL119; the uncertainty of the clinical trials process and whether the company`s product candidates, including XL119, will demonstrate safety and efficacy; and uncertainty regarding the ability of the company to enroll patients in a timely manner. These and other risk factors are discussed under "Risk Factors" and elsewhere in our quarterly report on Form 10-Q for the quarter ended March 31, 2004 and other filings with the Securities and Exchange Commission. The company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company`s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
NOTE: Exelixis and the Exelixis logo are registered U.S. trademarks. Spectrum selective kinase inhibitor is a trademark of Exelixis, Inc.
SOURCE Exelixis, Inc.
Jane M. Green, Ph.D., VP, Corporate Communications of Exelixis, Inc., +1-650-837-7579, or jmgreen@exelixis.com
http://www.exelixis.com
Copyright (C) 2004 PR Newswire. All rights reserved.
JS200
Leider funktioniert mein Alter Tread nicht mehr, da uch zu sehr mit LAMP beschäftigt bin, habe ich EXEL vernachlässigt, schade
JS200
JS200
RAiDAR alerts Learn More About RAiDAR-LT
06/23/2004 (06:00 ET) Exelixis Initiates Phase 3 Clinical Trial of XL119 in Bile Duct Cancer - PR Newswire
06/21/2004 (15:35 ET) EXEL: Filed New Form 4 - Edgar
06/17/2004 (20:17 ET) EXEL: Filed New Form 4 - Edgar
06/17/2004 (20:15 ET) EXEL: Filed New Form 3 - Edgar
06/16/2004 (16:21 ET) EXEL: Jumps +1.74%; Vol +66%; Last 90 Min of Trading - Knobias
06/14/2004 (14:47 ET) EXEL: Filed New Form 4 - Edgar
06/10/2004 (15:02 ET) EXEL: To Present At Pacific Growth Conference @ 17:00 ET - Knobias
06/10/2004 (01:58 ET) FirstAlert: 5 p.m. Investrend / Bestcalls - Investrend
06/08/2004 (10:02 ET) EXEL: To Present At Goldman Sachs Health Conference @ 11:40 ET - Knobias
06/04/2004 (16:00 ET) Exelixis to Webcast Presentation at the Pacific Growth Equities Life Sciences Growth Conference - PR Newswire
06/03/2004 (20:39 ET) EXEL: Filed New Form 4 - Edgar
06/03/2004 (16:40 ET) /C O R R E C T I O N -- Exelixis, Inc./ - PR Newswire
06/03/2004 (16:25 ET) StreetInsider Alert for EXEL - Street Insider
06/03/2004 (16:17 ET) Exelixis Initiates Phase 1 Trial for Anticancer Compound Xl647 - PR Newswire
06/03/2004 (08:02 ET) EXEL: To Present At Friedman Billings Conference @ 10:00 ET - Knobias
06/02/2004 (23:38 ET) Sector: After Hours Trading Focused on Medical World - Knobias
06/01/2004 (19:51 ET) Exelixis to Webcast Presentation at the Goldman Sachs 25th Annual Healthcare Conference - PR Newswire
05/27/2004 (06:43 ET) INDUSTRY: Merrill Examines Rate-Effect on Biotech Stocks - Knobias
05/26/2004 (16:00 ET) Exelixis to Webcast Presentation at the Friedman Billings Ramsey 8th Annual Growth Investor Conference - PR Newswire
05/25/2004 (16:21 ET) EXEL: Jumps +1.75%; Vol +89%; Last 90 Min of Trading - Knobias
JS200
06/23/2004 (06:00 ET) Exelixis Initiates Phase 3 Clinical Trial of XL119 in Bile Duct Cancer - PR Newswire
06/21/2004 (15:35 ET) EXEL: Filed New Form 4 - Edgar
06/17/2004 (20:17 ET) EXEL: Filed New Form 4 - Edgar
06/17/2004 (20:15 ET) EXEL: Filed New Form 3 - Edgar
06/16/2004 (16:21 ET) EXEL: Jumps +1.74%; Vol +66%; Last 90 Min of Trading - Knobias
06/14/2004 (14:47 ET) EXEL: Filed New Form 4 - Edgar
06/10/2004 (15:02 ET) EXEL: To Present At Pacific Growth Conference @ 17:00 ET - Knobias
06/10/2004 (01:58 ET) FirstAlert: 5 p.m. Investrend / Bestcalls - Investrend
06/08/2004 (10:02 ET) EXEL: To Present At Goldman Sachs Health Conference @ 11:40 ET - Knobias
06/04/2004 (16:00 ET) Exelixis to Webcast Presentation at the Pacific Growth Equities Life Sciences Growth Conference - PR Newswire
06/03/2004 (20:39 ET) EXEL: Filed New Form 4 - Edgar
06/03/2004 (16:40 ET) /C O R R E C T I O N -- Exelixis, Inc./ - PR Newswire
06/03/2004 (16:25 ET) StreetInsider Alert for EXEL - Street Insider
06/03/2004 (16:17 ET) Exelixis Initiates Phase 1 Trial for Anticancer Compound Xl647 - PR Newswire
06/03/2004 (08:02 ET) EXEL: To Present At Friedman Billings Conference @ 10:00 ET - Knobias
06/02/2004 (23:38 ET) Sector: After Hours Trading Focused on Medical World - Knobias
06/01/2004 (19:51 ET) Exelixis to Webcast Presentation at the Goldman Sachs 25th Annual Healthcare Conference - PR Newswire
05/27/2004 (06:43 ET) INDUSTRY: Merrill Examines Rate-Effect on Biotech Stocks - Knobias
05/26/2004 (16:00 ET) Exelixis to Webcast Presentation at the Friedman Billings Ramsey 8th Annual Growth Investor Conference - PR Newswire
05/25/2004 (16:21 ET) EXEL: Jumps +1.75%; Vol +89%; Last 90 Min of Trading - Knobias
JS200
MARKET: Stocks Lifted By Consumer Confidence; 2-Year High
Tuesday , June 29, 2004 10:28 ET
After a mixed opening, stocks were able to gain momentum and move higher, helped by a strong consumer confidence number reported by The Conference Board. According to the report, June`s consumer confidence hit a 2-year high of 101.9, well above May`s 93.2. Economists were expected 95.0. Retail stocks are being hit after disappointing forecast from Wal-Mart (WMT) and Target (TGT). Today`s Redbook report shows chain store sales as flat, while the ICSC/UBS Chain Store Sales Index fell 1.2% for the week. Interest sensitive stocks are also weak ahead of tomorrow interest rate hike. Leading the charge downward is Washington Mutual (WM) after lowering FY04 forecast, citing rising interest rates. JMP Securities also issued comments regarding interest rate sensitive homebuilders.
Economic Data
The Conference Board Consumer Confidence
Previous (May): 93.2
Consensus (June): 95.0
Actual (June): 101.9
EARLY GAINERS
(+) CLWT: Report Strong Year-End; Announces 5-for-10 Stock Dividend
(+) OMG: McDonald and Keybanc Upgrades to BUY
(+) ATI: Continues Run from Guidance; Upgraded by CIBC
(+) AM: Q1 Results 6c vs 27c; EPS -78% Y/Y; Mixes Guidance
(+) BABY: Restructure & Workforce Reduction; Divest Neogenesis
(+) ROCK: Raises Guidance; Sees Q2 EPS 72-75c vs 61c Estimate
(+) AMD: Susquehanna Believes AMD May Have Relationship With DELL
(+) AIRT: Continues Strong Run After Earnings Last Week
(+) FMTI: Raises FY04 Revenue Guidance
(+) EXEL: Submits IND to FDA for XL999 Anticancer Compound
(+) UBSH: Approves Buyback of 150K Shares
(+) NYMX: New Findings re Alzheimer`s Presented at Conference
EARLY LOSERS
(-) EP: Cuts 2004 Production Forecast; To Eliminate 17% of Workforce
(-) TGT: Lowers June Same-Store Sales `Well Below Plan`
(-) WM: Lowers FY04 Forecast, Cuts Jobs; Cites Interest Rates
(-) HAL: Sees Additional Q2 Additional Losses of (46c) per share
(-) HUBG: Prices Public Offering of Class A Common
(-) FLWS: Sees Q4 & FY 2004 Revenues BELOW Consensus
(-) NPSN: 2004 Provisional Results; Operating Profit UP
SECTOR: Banks/Mortgage
On the heels of the first interest rate increase since 2000, banking and mortgage stocks are making headlines. Washington Mutual (WM) cited rising interest rates when lowering FY04 forecast. Countrywide Financial (CFC) came out with positive comments in light of rising rates. WM (-8%), WFC (-1%), GDW (-1%), CFC (-3%), EELN (-1%), NCEN (-1%)
SECTOR: Retail
According to Redbook Research`s latest indicator, chain store sales were FLAT in the fourth week of June vs. May, below the target for a +0.6% gain. On an unadjusted basis, sales at major retailers for the week ended June 26 increased by 3.2% from the same week in 2003, down from the 4.7% pace in the preceding week. On a seasonally adjusted basis, sales in the four-week period rose 4.5% from the same period in 2003. Sales growth at U.S. chain stores slowed further in the latest week, as rainy and cool weather dampened retailers hopes for a strong month. "Retailers blamed the weather, noting that untypically cool and rainy conditions had cut into their seasonal business," the report said.
The ICSC/UBS Chain Store Sales Index fell by 1.2% for the week compared to a 0.1% gain previously. This figure reflects the second largest decline this year. On a Y/Y basis, the index increased by 4.2% after rising by 4.9% in the previous week. As a result, ICSC lowered its sales projection for June from 4.5%-5.0% to 3.0%-3.5% on a year-over-year comparison.
Following Wal-Mart`s (WMT) trend from Monday, Target (TGT) came out today lowering its outlook for June same-store sales. TGT now sees June sales "well below plan".
SECTOR: Homebuilders
JMP Securities expects one more year of earnings-driven outperformance for Homebuilding stocks but believes the road will remain bumpy. After roughly doubling in 2003, stocks have been highly volatile so far in 2004 and have performed modestly better than the overall market, rising approximately 5% vs +3% for the S&P and flat for the Dow and NASDAQ. The stock market is concerned, however, that imminent Fed tightening will lead to an end to the current housing cycle. They think the best positioned companies for a higher interest rate environment should be focused on the high-end and retirement segments of the market, such as MDC, MTH, PHM, SPF, JOE, and TOL.
JS200
Tuesday , June 29, 2004 10:28 ET
After a mixed opening, stocks were able to gain momentum and move higher, helped by a strong consumer confidence number reported by The Conference Board. According to the report, June`s consumer confidence hit a 2-year high of 101.9, well above May`s 93.2. Economists were expected 95.0. Retail stocks are being hit after disappointing forecast from Wal-Mart (WMT) and Target (TGT). Today`s Redbook report shows chain store sales as flat, while the ICSC/UBS Chain Store Sales Index fell 1.2% for the week. Interest sensitive stocks are also weak ahead of tomorrow interest rate hike. Leading the charge downward is Washington Mutual (WM) after lowering FY04 forecast, citing rising interest rates. JMP Securities also issued comments regarding interest rate sensitive homebuilders.
Economic Data
The Conference Board Consumer Confidence
Previous (May): 93.2
Consensus (June): 95.0
Actual (June): 101.9
EARLY GAINERS
(+) CLWT: Report Strong Year-End; Announces 5-for-10 Stock Dividend
(+) OMG: McDonald and Keybanc Upgrades to BUY
(+) ATI: Continues Run from Guidance; Upgraded by CIBC
(+) AM: Q1 Results 6c vs 27c; EPS -78% Y/Y; Mixes Guidance
(+) BABY: Restructure & Workforce Reduction; Divest Neogenesis
(+) ROCK: Raises Guidance; Sees Q2 EPS 72-75c vs 61c Estimate
(+) AMD: Susquehanna Believes AMD May Have Relationship With DELL
(+) AIRT: Continues Strong Run After Earnings Last Week
(+) FMTI: Raises FY04 Revenue Guidance
(+) EXEL: Submits IND to FDA for XL999 Anticancer Compound
(+) UBSH: Approves Buyback of 150K Shares
(+) NYMX: New Findings re Alzheimer`s Presented at Conference
EARLY LOSERS
(-) EP: Cuts 2004 Production Forecast; To Eliminate 17% of Workforce
(-) TGT: Lowers June Same-Store Sales `Well Below Plan`
(-) WM: Lowers FY04 Forecast, Cuts Jobs; Cites Interest Rates
(-) HAL: Sees Additional Q2 Additional Losses of (46c) per share
(-) HUBG: Prices Public Offering of Class A Common
(-) FLWS: Sees Q4 & FY 2004 Revenues BELOW Consensus
(-) NPSN: 2004 Provisional Results; Operating Profit UP
SECTOR: Banks/Mortgage
On the heels of the first interest rate increase since 2000, banking and mortgage stocks are making headlines. Washington Mutual (WM) cited rising interest rates when lowering FY04 forecast. Countrywide Financial (CFC) came out with positive comments in light of rising rates. WM (-8%), WFC (-1%), GDW (-1%), CFC (-3%), EELN (-1%), NCEN (-1%)
SECTOR: Retail
According to Redbook Research`s latest indicator, chain store sales were FLAT in the fourth week of June vs. May, below the target for a +0.6% gain. On an unadjusted basis, sales at major retailers for the week ended June 26 increased by 3.2% from the same week in 2003, down from the 4.7% pace in the preceding week. On a seasonally adjusted basis, sales in the four-week period rose 4.5% from the same period in 2003. Sales growth at U.S. chain stores slowed further in the latest week, as rainy and cool weather dampened retailers hopes for a strong month. "Retailers blamed the weather, noting that untypically cool and rainy conditions had cut into their seasonal business," the report said.
The ICSC/UBS Chain Store Sales Index fell by 1.2% for the week compared to a 0.1% gain previously. This figure reflects the second largest decline this year. On a Y/Y basis, the index increased by 4.2% after rising by 4.9% in the previous week. As a result, ICSC lowered its sales projection for June from 4.5%-5.0% to 3.0%-3.5% on a year-over-year comparison.
Following Wal-Mart`s (WMT) trend from Monday, Target (TGT) came out today lowering its outlook for June same-store sales. TGT now sees June sales "well below plan".
SECTOR: Homebuilders
JMP Securities expects one more year of earnings-driven outperformance for Homebuilding stocks but believes the road will remain bumpy. After roughly doubling in 2003, stocks have been highly volatile so far in 2004 and have performed modestly better than the overall market, rising approximately 5% vs +3% for the S&P and flat for the Dow and NASDAQ. The stock market is concerned, however, that imminent Fed tightening will lead to an end to the current housing cycle. They think the best positioned companies for a higher interest rate environment should be focused on the high-end and retirement segments of the market, such as MDC, MTH, PHM, SPF, JOE, and TOL.
JS200
RAiDAR alerts Learn More About RAiDAR-LT
06/29/2004 (10:28 ET) MARKET: Stocks Lifted By Consumer Confidence; 2-Year High - Knobias
06/29/2004 (09:10 ET) MARKET: Future Slide; Mixed Opening Led By Retail & Banks - Knobias
06/29/2004 (08:00 ET) StreetInsider Alert for EXEL - Street Insider
06/29/2004 (07:59 ET) MARKET: Futures Up Slightly; Banks, Rates & Retail Set Pace - Knobias
06/29/2004 (07:10 ET) EXEL: Submits IND to FDA for XL999 Anticancer Compound - Knobias
06/29/2004 (06:00 ET) Exelixis Files IND Application for Anticancer Compound XL999 - PR Newswire
06/28/2004 (07:50 ET) INDUSTRY: Lehman Cuts Biotechnology Stocks to Neutral - Knobias
06/25/2004 (16:27 ET) EXEL: Volume Spike; 127% > 20-adsv, Stock +3.98% - Knobias
06/25/2004 (16:21 ET) EXEL: Jumps +1.64%; Vol +121%; Last 90 Min of Trading - Knobias
06/24/2004 (16:16 ET) EXEL: Short Interest UP 8.5% to 2.5M in Jun 2004 - Knobias
06/24/2004 (12:17 ET) EXEL: Filed New Form 4 - Edgar
06/23/2004 (16:21 ET) EXEL: Jumps +3.66%; Vol +252%; Last 90 Min of Trading - Knobias
06/23/2004 (07:14 ET) EXEL: Phase 3 Trial of XL119; Survival is Primary Endpoint - Knobias
06/23/2004 (06:00 ET) Exelixis Initiates Phase 3 Clinical Trial of XL119 in Bile Duct Cancer - PR Newswire
06/21/2004 (15:35 ET) EXEL: Filed New Form 4 - Edgar
06/17/2004 (20:17 ET) EXEL: Filed New Form 4 - Edgar
06/17/2004 (20:15 ET) EXEL: Filed New Form 3 - Edgar
06/16/2004 (16:21 ET) EXEL: Jumps +1.74%; Vol +66%; Last 90 Min of Trading - Knobias
06/14/2004 (14:47 ET) EXEL: Filed New Form 4 - Edgar
06/10/2004 (15:02 ET) EXEL: To Present At Pacific Growth Conference @ 17:00 ET - Knobias
06/10/2004 (01:58 ET) FirstAlert: 5 p.m. Investrend / Bestcalls - Investrend
06/08/2004 (10:02 ET) EXEL: To Present At Goldman Sachs Health Conference @ 11:40 ET - Knobias
06/04/2004 (16:00 ET) Exelixis to Webcast Presentation at the Pacific Growth Equities Life Sciences Growth Conference - PR Newswire
06/03/2004 (20:39 ET) EXEL: Filed New Form 4 - Edgar
06/03/2004 (16:40 ET) /C O R R E C T I O N -- Exelixis, Inc./ - PR Newswire
JS200
06/29/2004 (10:28 ET) MARKET: Stocks Lifted By Consumer Confidence; 2-Year High - Knobias
06/29/2004 (09:10 ET) MARKET: Future Slide; Mixed Opening Led By Retail & Banks - Knobias
06/29/2004 (08:00 ET) StreetInsider Alert for EXEL - Street Insider
06/29/2004 (07:59 ET) MARKET: Futures Up Slightly; Banks, Rates & Retail Set Pace - Knobias
06/29/2004 (07:10 ET) EXEL: Submits IND to FDA for XL999 Anticancer Compound - Knobias
06/29/2004 (06:00 ET) Exelixis Files IND Application for Anticancer Compound XL999 - PR Newswire
06/28/2004 (07:50 ET) INDUSTRY: Lehman Cuts Biotechnology Stocks to Neutral - Knobias
06/25/2004 (16:27 ET) EXEL: Volume Spike; 127% > 20-adsv, Stock +3.98% - Knobias
06/25/2004 (16:21 ET) EXEL: Jumps +1.64%; Vol +121%; Last 90 Min of Trading - Knobias
06/24/2004 (16:16 ET) EXEL: Short Interest UP 8.5% to 2.5M in Jun 2004 - Knobias
06/24/2004 (12:17 ET) EXEL: Filed New Form 4 - Edgar
06/23/2004 (16:21 ET) EXEL: Jumps +3.66%; Vol +252%; Last 90 Min of Trading - Knobias
06/23/2004 (07:14 ET) EXEL: Phase 3 Trial of XL119; Survival is Primary Endpoint - Knobias
06/23/2004 (06:00 ET) Exelixis Initiates Phase 3 Clinical Trial of XL119 in Bile Duct Cancer - PR Newswire
06/21/2004 (15:35 ET) EXEL: Filed New Form 4 - Edgar
06/17/2004 (20:17 ET) EXEL: Filed New Form 4 - Edgar
06/17/2004 (20:15 ET) EXEL: Filed New Form 3 - Edgar
06/16/2004 (16:21 ET) EXEL: Jumps +1.74%; Vol +66%; Last 90 Min of Trading - Knobias
06/14/2004 (14:47 ET) EXEL: Filed New Form 4 - Edgar
06/10/2004 (15:02 ET) EXEL: To Present At Pacific Growth Conference @ 17:00 ET - Knobias
06/10/2004 (01:58 ET) FirstAlert: 5 p.m. Investrend / Bestcalls - Investrend
06/08/2004 (10:02 ET) EXEL: To Present At Goldman Sachs Health Conference @ 11:40 ET - Knobias
06/04/2004 (16:00 ET) Exelixis to Webcast Presentation at the Pacific Growth Equities Life Sciences Growth Conference - PR Newswire
06/03/2004 (20:39 ET) EXEL: Filed New Form 4 - Edgar
06/03/2004 (16:40 ET) /C O R R E C T I O N -- Exelixis, Inc./ - PR Newswire
JS200
Trading Spotlight
Exelixis Agrees to Acquire X-Ceptor Therapeutics
via COMTEX
September 28, 2004
SOUTH SAN FRANCISCO, Calif., Sep 28, 2004 /PRNewswire-FirstCall via COMTEX/ --
Exelixis, Inc. (Nasdaq: EXEL) announced today that it has entered into a definitive agreement to acquire X-Ceptor Therapeutics, Inc., a leader in the discovery and development of small molecules that modulate nuclear hormone receptors (NHRs). Under the terms of the agreement, Exelixis will issue approximately 2.5 million shares of Exelixis common stock and pay approximately $2.9 million in cash in exchange for all of the outstanding shares of capital stock of X-Ceptor on a fully-diluted basis. X-Ceptor stockholders who own approximately 87% of the X-Ceptor shares outstanding have executed written consents to approve the transaction. The acquisition is expected to close in the fourth quarter 2004 subject to customary closing conditions.
NHRs represent a promising class of clinically and commercially validated gene targets that are implicated in a wide range of metabolic and cardiovascular disorders. The combination of Exelixis` small molecule discovery engine and oncology pipeline with X-Ceptor`s proprietary "reverse endocrinology" platform and pipeline of NHR-targeted compounds advances Exelixis` strategy to diversify into new therapeutic areas and is expected to accelerate the development and commercialization of a diverse, highly differentiated pipeline of products to treat diseases including metabolic syndrome, lipid disorders, hypertension and congestive heart failure.
"We believe that the acquisition of X-Ceptor will bring greater value and breadth to Exelixis` development pipeline by adding compounds that target important metabolic and cardiovascular diseases and that complement our cancer drug development programs," said George A. Scangos, Exelixis president and chief executive officer. "We consider X-Ceptor to be the `best in class` company developing small molecule NHR-based therapies. X-Ceptor`s management and advisors include a group of internationally recognized scientific pioneers, including Dr. Ronald Evans of The Salk Institute and the Howard Hughes Medical Institute, and Dr. Richard Heyman, X-Ceptor`s chief scientific officer. By integrating X-Ceptor`s scientific excellence and expertise in NHRs with Exelixis` powerful small molecule discovery and development engine, we expect to speed the development of important new therapeutics for diseases that affect millions of people worldwide."
"The X-Ceptor-Exelixis combination represents a unique opportunity to solidify a leadership position in hormone receptor-based drug development and rapidly advance an exciting pipeline of novel metabolic and cardiovascular compounds," said Richard Heyman, Ph.D., chief scientific officer. "We believe that Exelixis` proven expertise in kinase-based discovery and development joined to X-Ceptor`s pioneering insights into the NHR gene family will allow us to exploit the therapeutic and commercial potential of this exciting gene family. We at X-Ceptor believe that we have built an exciting young company that through this timely acquisition now has the potential to significantly accelerate achieving its goals of delivering important new medicines to patients in need."
About Nuclear Receptors
The nuclear receptor gene family is a therapeutically rich target class implicated in a broad range of human diseases. Nuclear receptors are ligand-activated transcription factors that regulate gene expression and play a critical role in endocrine signaling. Nuclear receptors interact in a ligand-dependent manner with additional protein molecules that serve as co-activators or co-repressors. This allows each receptor to turn genes on or off in a gene and tissue-selective manner.
The 48 members of the nuclear receptor gene family can be divided into two main classes: "validated" nuclear receptors whose ligands and endocrine pathways are established and as a result serve as bona fide drug targets for human disease, including anti-inflammatory drugs such as glucocorticoids and insulin sensitizers such as the glitazones. In addition, a second class of nuclear receptors referred to as "orphan" nuclear receptors, whose ligands, target genes and physiological function are not completely understood, offer new first-in-class targets for large therapeutic areas, in particular, cardiovascular disease.
About X-Ceptor
X-Ceptor Therapeutics, Inc. (www.x-ceptor.com), founded in 1999, is a privately-held company focused on the discovery and development of novel small molecule therapeutics that modulate nuclear receptors. In less than four years, X-Ceptor has assembled a world-class scientific team of biologists, chemists and pharmacologists and developed a fully-integrated drug discovery platform for the nuclear receptor gene family. The company has taken identified orphan nuclear receptor targets without disease association and established disease proof-of-concept and generated advanced preclinical drug candidates. X-Ceptor has built an integrated drug discovery platform and has developed a portfolio of drug candidates to treat cardiovascular and metabolic disorders. In 2001, X-Ceptor and Sankyo Ltd. established a partnership for the discovery and development of small molecule modulators of LXR.
X-Ceptor`s "Reverse Endocrinology" Approach
X-Ceptor`s "reverse endocrinology" approach facilitates the company`s ability to validate targets, develop novel therapeutics and improve existing drugs rapidly and effectively. Traditional approaches to nuclear receptor drug discovery place an emphasis on the classical endocrinology process using a ligand to identify a receptor, which is then correlated to a disease. In contrast, X-Ceptor uses a reverse endocrinology strategy that allows a parallel approach to target validation and drug discovery. The company begins with the molecular target that is used to rapidly screen for candidate ligands. The resulting small molecule "hits" are optimized for their receptor activity and specificity with medicinal chemistry and rational drug design employing x-ray crystallography of the ligand receptor complex.
X-Ceptor`s Development Pipeline
The company`s lead drug discovery programs include compounds directed against:
-- Liver X Receptor (LXR) to treat the process of reverse cholesterol transport, partnered with Sankyo; -- Farnesoid X Receptor (FXR) to treat hypertriglyceridemia (high triglycerides) observed in type II diabetes, metabolic syndrome and related metabolic disorders; -- Mineralocortiocoid receptor (MR), for the treatment of hypertension and other cardiovascular disorders; -- Other novel approaches to the treatment of diabetes and obesity.
Exelixis anticipates filing IND applications for some of these compounds during 2006.
Exelixis` management will discuss the agreement to acquire X-Ceptor Therapeutics during a conference call beginning at 10:00 am U.S. EDT today, Tuesday, September 28, 2004. To participate in the conference call, log onto www.exelixis.com and click on the webcast link under the heading "Investor Info" to access the live call. A copy of Exelixis` press releases, including this release, can be found on the company`s website at www.exelixis.com under the heading "Press Room."
About Exelixis
Exelixis, Inc. is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis` development pipeline includes: XL119 (becatecarin), for which a Phase 3 clinical trial has been initiated in patients with bile duct tumors; XL784, which has completed a Phase 1 clinical trial; XL647, which is currently in a Phase 1 clinical trial; XL999, for which an IND application has been filed; XL880, XL820, XL844 and XL184, anticancer compounds that are potential IND candidates; and multiple compounds in preclinical development in metabolic and cardiovascular disease through the proposed acquisition of X-Ceptor Therapeutics, Inc. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline (GSK) and Bristol-Myers Squibb Company. Pursuant to a product development and commercialization agreement between Exelixis and GSK, GSK has the option, after completion of Phase 2a clinical trials, to elect to develop a certain number of compounds in Exelixis` product pipeline, which may include the cancer compounds identified in this press release (other than the company`s cancer compound XL119), thus potentially triggering milestone payments and royalties from GSK and co-promotion rights by Exelixis. The company has also established agricultural research collaborations with Bayer CropScience, Dow AgroSciences and Renessen LLC. Other partners include Merck & Co., Inc., Schering-Plough Research Institute, Inc., Cytokinetics, Inc., Elan Pharmaceuticals, Inc. and Scios Inc. For more information, please visit the company`s web site at www.exelixis.com.
This press release contains forward-looking statements, including without limitation all statements related to the timing and intended benefits of the acquisition of X-Ceptor Therapeutics, Exelixis` plans to advance its program in metabolic diseases, as well as plans to conduct a Phase 3 clinical trial of XL119 and the therapeutic and commercial potential of XL647, XL119, XL999, XL844, XL820, XL880 and other compounds in Exelixis preclinical pipeline. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "slated," "goal" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis` current expectations. Forward-looking statements involve risks and uncertainties. Exelixis` actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the ability of the company to successfully complete the acquisition of X-Ceptor Therapeutics in the intended timeframe or at all; the ability of the company to advance preclinical compounds in cardiovascular and metabolic diseases into clinical trials; the ability and timing, if ever, of the company to demonstrate therapeutic or commercial value of the assets acquired from X-Ceptor; the ability of the company to successfully conduct the Phase 3 clinical trial of XL119; The ability of the company to advance additional preclinical compounds into clinical development; and the uncertainty of the FDA approval process with respect to and commercial value of these compounds. These and other risk factors are discussed under "Risk Factors" and elsewhere in our quarterly report on Form 10-Q for the quarter ended June 30, 2004 and other filings with the Securities and Exchange Commission. The company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company`s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
NOTE: Exelixis and the Exelixis logo are registered U.S. trademarks. Spectrum Selective Kinase Inhibitor is a trademark of Exelixis, Inc.
SOURCE Exelixis, Inc.
Frank Karbe, Chief Financial Officer of Exelixis, Inc., +1-650-837-7565, or fkarbe@exelixis.com; or Richard A. Heyman, Ph.D., Chief Scientific Officer of X-Ceptor Therapeutics, +1-858-458-4581, or rheyman@X-ceptor.com http://www.x-ceptor.com
Copyright (C) 2004 PR Newswire. All rights reserved.
via COMTEX
September 28, 2004
SOUTH SAN FRANCISCO, Calif., Sep 28, 2004 /PRNewswire-FirstCall via COMTEX/ --
Exelixis, Inc. (Nasdaq: EXEL) announced today that it has entered into a definitive agreement to acquire X-Ceptor Therapeutics, Inc., a leader in the discovery and development of small molecules that modulate nuclear hormone receptors (NHRs). Under the terms of the agreement, Exelixis will issue approximately 2.5 million shares of Exelixis common stock and pay approximately $2.9 million in cash in exchange for all of the outstanding shares of capital stock of X-Ceptor on a fully-diluted basis. X-Ceptor stockholders who own approximately 87% of the X-Ceptor shares outstanding have executed written consents to approve the transaction. The acquisition is expected to close in the fourth quarter 2004 subject to customary closing conditions.
NHRs represent a promising class of clinically and commercially validated gene targets that are implicated in a wide range of metabolic and cardiovascular disorders. The combination of Exelixis` small molecule discovery engine and oncology pipeline with X-Ceptor`s proprietary "reverse endocrinology" platform and pipeline of NHR-targeted compounds advances Exelixis` strategy to diversify into new therapeutic areas and is expected to accelerate the development and commercialization of a diverse, highly differentiated pipeline of products to treat diseases including metabolic syndrome, lipid disorders, hypertension and congestive heart failure.
"We believe that the acquisition of X-Ceptor will bring greater value and breadth to Exelixis` development pipeline by adding compounds that target important metabolic and cardiovascular diseases and that complement our cancer drug development programs," said George A. Scangos, Exelixis president and chief executive officer. "We consider X-Ceptor to be the `best in class` company developing small molecule NHR-based therapies. X-Ceptor`s management and advisors include a group of internationally recognized scientific pioneers, including Dr. Ronald Evans of The Salk Institute and the Howard Hughes Medical Institute, and Dr. Richard Heyman, X-Ceptor`s chief scientific officer. By integrating X-Ceptor`s scientific excellence and expertise in NHRs with Exelixis` powerful small molecule discovery and development engine, we expect to speed the development of important new therapeutics for diseases that affect millions of people worldwide."
"The X-Ceptor-Exelixis combination represents a unique opportunity to solidify a leadership position in hormone receptor-based drug development and rapidly advance an exciting pipeline of novel metabolic and cardiovascular compounds," said Richard Heyman, Ph.D., chief scientific officer. "We believe that Exelixis` proven expertise in kinase-based discovery and development joined to X-Ceptor`s pioneering insights into the NHR gene family will allow us to exploit the therapeutic and commercial potential of this exciting gene family. We at X-Ceptor believe that we have built an exciting young company that through this timely acquisition now has the potential to significantly accelerate achieving its goals of delivering important new medicines to patients in need."
About Nuclear Receptors
The nuclear receptor gene family is a therapeutically rich target class implicated in a broad range of human diseases. Nuclear receptors are ligand-activated transcription factors that regulate gene expression and play a critical role in endocrine signaling. Nuclear receptors interact in a ligand-dependent manner with additional protein molecules that serve as co-activators or co-repressors. This allows each receptor to turn genes on or off in a gene and tissue-selective manner.
The 48 members of the nuclear receptor gene family can be divided into two main classes: "validated" nuclear receptors whose ligands and endocrine pathways are established and as a result serve as bona fide drug targets for human disease, including anti-inflammatory drugs such as glucocorticoids and insulin sensitizers such as the glitazones. In addition, a second class of nuclear receptors referred to as "orphan" nuclear receptors, whose ligands, target genes and physiological function are not completely understood, offer new first-in-class targets for large therapeutic areas, in particular, cardiovascular disease.
About X-Ceptor
X-Ceptor Therapeutics, Inc. (www.x-ceptor.com), founded in 1999, is a privately-held company focused on the discovery and development of novel small molecule therapeutics that modulate nuclear receptors. In less than four years, X-Ceptor has assembled a world-class scientific team of biologists, chemists and pharmacologists and developed a fully-integrated drug discovery platform for the nuclear receptor gene family. The company has taken identified orphan nuclear receptor targets without disease association and established disease proof-of-concept and generated advanced preclinical drug candidates. X-Ceptor has built an integrated drug discovery platform and has developed a portfolio of drug candidates to treat cardiovascular and metabolic disorders. In 2001, X-Ceptor and Sankyo Ltd. established a partnership for the discovery and development of small molecule modulators of LXR.
X-Ceptor`s "Reverse Endocrinology" Approach
X-Ceptor`s "reverse endocrinology" approach facilitates the company`s ability to validate targets, develop novel therapeutics and improve existing drugs rapidly and effectively. Traditional approaches to nuclear receptor drug discovery place an emphasis on the classical endocrinology process using a ligand to identify a receptor, which is then correlated to a disease. In contrast, X-Ceptor uses a reverse endocrinology strategy that allows a parallel approach to target validation and drug discovery. The company begins with the molecular target that is used to rapidly screen for candidate ligands. The resulting small molecule "hits" are optimized for their receptor activity and specificity with medicinal chemistry and rational drug design employing x-ray crystallography of the ligand receptor complex.
X-Ceptor`s Development Pipeline
The company`s lead drug discovery programs include compounds directed against:
-- Liver X Receptor (LXR) to treat the process of reverse cholesterol transport, partnered with Sankyo; -- Farnesoid X Receptor (FXR) to treat hypertriglyceridemia (high triglycerides) observed in type II diabetes, metabolic syndrome and related metabolic disorders; -- Mineralocortiocoid receptor (MR), for the treatment of hypertension and other cardiovascular disorders; -- Other novel approaches to the treatment of diabetes and obesity.
Exelixis anticipates filing IND applications for some of these compounds during 2006.
Exelixis` management will discuss the agreement to acquire X-Ceptor Therapeutics during a conference call beginning at 10:00 am U.S. EDT today, Tuesday, September 28, 2004. To participate in the conference call, log onto www.exelixis.com and click on the webcast link under the heading "Investor Info" to access the live call. A copy of Exelixis` press releases, including this release, can be found on the company`s website at www.exelixis.com under the heading "Press Room."
About Exelixis
Exelixis, Inc. is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis` development pipeline includes: XL119 (becatecarin), for which a Phase 3 clinical trial has been initiated in patients with bile duct tumors; XL784, which has completed a Phase 1 clinical trial; XL647, which is currently in a Phase 1 clinical trial; XL999, for which an IND application has been filed; XL880, XL820, XL844 and XL184, anticancer compounds that are potential IND candidates; and multiple compounds in preclinical development in metabolic and cardiovascular disease through the proposed acquisition of X-Ceptor Therapeutics, Inc. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline (GSK) and Bristol-Myers Squibb Company. Pursuant to a product development and commercialization agreement between Exelixis and GSK, GSK has the option, after completion of Phase 2a clinical trials, to elect to develop a certain number of compounds in Exelixis` product pipeline, which may include the cancer compounds identified in this press release (other than the company`s cancer compound XL119), thus potentially triggering milestone payments and royalties from GSK and co-promotion rights by Exelixis. The company has also established agricultural research collaborations with Bayer CropScience, Dow AgroSciences and Renessen LLC. Other partners include Merck & Co., Inc., Schering-Plough Research Institute, Inc., Cytokinetics, Inc., Elan Pharmaceuticals, Inc. and Scios Inc. For more information, please visit the company`s web site at www.exelixis.com.
This press release contains forward-looking statements, including without limitation all statements related to the timing and intended benefits of the acquisition of X-Ceptor Therapeutics, Exelixis` plans to advance its program in metabolic diseases, as well as plans to conduct a Phase 3 clinical trial of XL119 and the therapeutic and commercial potential of XL647, XL119, XL999, XL844, XL820, XL880 and other compounds in Exelixis preclinical pipeline. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "slated," "goal" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis` current expectations. Forward-looking statements involve risks and uncertainties. Exelixis` actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the ability of the company to successfully complete the acquisition of X-Ceptor Therapeutics in the intended timeframe or at all; the ability of the company to advance preclinical compounds in cardiovascular and metabolic diseases into clinical trials; the ability and timing, if ever, of the company to demonstrate therapeutic or commercial value of the assets acquired from X-Ceptor; the ability of the company to successfully conduct the Phase 3 clinical trial of XL119; The ability of the company to advance additional preclinical compounds into clinical development; and the uncertainty of the FDA approval process with respect to and commercial value of these compounds. These and other risk factors are discussed under "Risk Factors" and elsewhere in our quarterly report on Form 10-Q for the quarter ended June 30, 2004 and other filings with the Securities and Exchange Commission. The company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company`s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
NOTE: Exelixis and the Exelixis logo are registered U.S. trademarks. Spectrum Selective Kinase Inhibitor is a trademark of Exelixis, Inc.
SOURCE Exelixis, Inc.
Frank Karbe, Chief Financial Officer of Exelixis, Inc., +1-650-837-7565, or fkarbe@exelixis.com; or Richard A. Heyman, Ph.D., Chief Scientific Officer of X-Ceptor Therapeutics, +1-858-458-4581, or rheyman@X-ceptor.com http://www.x-ceptor.com
Copyright (C) 2004 PR Newswire. All rights reserved.
09/30/2004 (17:16 ET) Exelixis Releases Pre-Clinical Data on Two Spectrum Selective Kinase Inhibitors in Development - XL647 and XL999 - at EORTC - PR Newswire
09/29/2004 (16:22 ET) EXEL: Jumps +1.88%; Vol +73%; Last 90 Min of Trading - Knobias
09/29/2004 (14:41 ET) EXEL: Filed New Form 4 - Edgar
09/29/2004 (13:02 ET) EXEL: To Present At UBS Life Sciences Conference @ 15:00 ET - Knobias
09/29/2004 (08:00 ET) StreetInsider Alert for EXEL - Street Insider
09/29/2004 (16:22 ET) EXEL: Jumps +1.88%; Vol +73%; Last 90 Min of Trading - Knobias
09/29/2004 (14:41 ET) EXEL: Filed New Form 4 - Edgar
09/29/2004 (13:02 ET) EXEL: To Present At UBS Life Sciences Conference @ 15:00 ET - Knobias
09/29/2004 (08:00 ET) StreetInsider Alert for EXEL - Street Insider
10/15/2004 (17:40 ET) EXEL: Filed New Form 4 - Edgar
10/08/2004 (20:42 ET) EXEL: Filed New Form 4 - Edgar
10/08/2004 (16:21 ET) EXEL: Drops -4.13%; Vol +59%; Last 90 Min of Trading - Knobias
10/07/2004 (16:21 ET) EXEL: Drops -2.98%; Vol +84%; Last 90 Min of Trading - Knobias
10/06/2004 (16:21 ET) EXEL: Jumps +1.22%; Vol +104%; Last 90 Min of Trading - Knobias
10/08/2004 (20:42 ET) EXEL: Filed New Form 4 - Edgar
10/08/2004 (16:21 ET) EXEL: Drops -4.13%; Vol +59%; Last 90 Min of Trading - Knobias
10/07/2004 (16:21 ET) EXEL: Drops -2.98%; Vol +84%; Last 90 Min of Trading - Knobias
10/06/2004 (16:21 ET) EXEL: Jumps +1.22%; Vol +104%; Last 90 Min of Trading - Knobias
Halogen Software Continues Strong Growth in Q3 - Latest product release and record number of new EPM customers support company`s substantial
via COMTEX
October 25, 2004
growth@
OTTAWA, Oct 25, 2004 (CNW Telbec via COMTEX) --
Halogen Software today announced continued positive growth in Q3, signing a record 30 new Employee Performance Management (EPM) customers and securing their position as the fastest-growing provider of web-based EPM software. Halogen Software also set another record for new license revenue and total revenue in the quarter.
Halogen Software`s award-winning products Halogen eAppraisal(TM) and Halogen eAppraisal(TM) Healthcare became the solution of choice for new clients this quarter including Phoenix Children`s Hospital, Exelixis Inc, Smith Northview Hospital, First Advantage Corp., Cinergy, Stephens Inc., and the City of Vancouver. The company also secured a contract with the State of Michigan for licenses of Halogen e360.
Positive growth was bolstered by the release of Halogen eAppraisal version 6.0 mid-quarter, the most complete, user-friendly, and affordable employee evaluation solution on the market. The latest version introduces several new product features, further improving productivity and ensuring quick, professional quality reviews.
About Halogen Software
Halogen Software Inc. is a leading provider of employee performance management (EPM) solutions. Founded in 2001 as a subsidiary of a successful consulting company, Halogen offers powerful, easy-to-use, and affordable Web- based software that dramatically improves HR and line-manager productivity. The company`s flagship product, Halogen eAppraisal(TM), automates and simplifies time-consuming employee appraisals. Halogen eAppraisal(TM) Healthcare, created specifically for the healthcare industry, helps healthcare organizations to simplify the task of performing appraisals and meeting accreditation criteria. Halogen e360(TM) automates and simplifies formal 360-degree feedback procedures and offers sophisticated performance reporting. For more information on Halogen Software, visit: www.halogensoftware.com.
VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION: http://www.newswire.ca/en/releases/orgDisplay.cgi?okey=77877
For further information: Media contact: Donna Ronayne, VP, Marketing & Business Development, 613.744.2254 x 320, dronayne(at)halogensoftware.com News release via Canada NewsWire, Ottawa 613-563-4465
Copyright (C) 2004 CNW, All rights reserved
via COMTEX
October 25, 2004
growth@
OTTAWA, Oct 25, 2004 (CNW Telbec via COMTEX) --
Halogen Software today announced continued positive growth in Q3, signing a record 30 new Employee Performance Management (EPM) customers and securing their position as the fastest-growing provider of web-based EPM software. Halogen Software also set another record for new license revenue and total revenue in the quarter.
Halogen Software`s award-winning products Halogen eAppraisal(TM) and Halogen eAppraisal(TM) Healthcare became the solution of choice for new clients this quarter including Phoenix Children`s Hospital, Exelixis Inc, Smith Northview Hospital, First Advantage Corp., Cinergy, Stephens Inc., and the City of Vancouver. The company also secured a contract with the State of Michigan for licenses of Halogen e360.
Positive growth was bolstered by the release of Halogen eAppraisal version 6.0 mid-quarter, the most complete, user-friendly, and affordable employee evaluation solution on the market. The latest version introduces several new product features, further improving productivity and ensuring quick, professional quality reviews.
About Halogen Software
Halogen Software Inc. is a leading provider of employee performance management (EPM) solutions. Founded in 2001 as a subsidiary of a successful consulting company, Halogen offers powerful, easy-to-use, and affordable Web- based software that dramatically improves HR and line-manager productivity. The company`s flagship product, Halogen eAppraisal(TM), automates and simplifies time-consuming employee appraisals. Halogen eAppraisal(TM) Healthcare, created specifically for the healthcare industry, helps healthcare organizations to simplify the task of performing appraisals and meeting accreditation criteria. Halogen e360(TM) automates and simplifies formal 360-degree feedback procedures and offers sophisticated performance reporting. For more information on Halogen Software, visit: www.halogensoftware.com.
VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION: http://www.newswire.ca/en/releases/orgDisplay.cgi?okey=77877
For further information: Media contact: Donna Ronayne, VP, Marketing & Business Development, 613.744.2254 x 320, dronayne(at)halogensoftware.com News release via Canada NewsWire, Ottawa 613-563-4465
Copyright (C) 2004 CNW, All rights reserved
10/25/2004 (08:32 ET) Halogen Software Continues Strong Growth in Q3 - Latest product release and record number of new EPM customers support company`s substantial - Canada NewsWire
10/25/2004 (06:46 ET) EXEL: Initiates Ph I Clinical Trial for XL999 - Knobias
10/25/2004 (06:01 ET) Exelixis Initiates Phase 1 Clinical Trial for XL999 - PR Newswire
10/21/2004 (20:16 ET) EXEL: Filed New Form 4 - Edgar
10/21/2004 (08:14 ET) EXEL: Filed 8-K Regarding Acq. of X-Ceptor (Oct-19 PR) - Knobias
10/25/2004 (06:46 ET) EXEL: Initiates Ph I Clinical Trial for XL999 - Knobias
10/25/2004 (06:01 ET) Exelixis Initiates Phase 1 Clinical Trial for XL999 - PR Newswire
10/21/2004 (20:16 ET) EXEL: Filed New Form 4 - Edgar
10/21/2004 (08:14 ET) EXEL: Filed 8-K Regarding Acq. of X-Ceptor (Oct-19 PR) - Knobias
10/29/2004 (07:20 ET) TABLE: Unconfirmed Earnings Expected Thursday, Nov 4 - Knobias
10/27/2004 (08:12 ET) EXEL: Files $200M Universal Shelf Registration - Knobias
10/27/2004 (06:07 ET) EXEL: Filed New Form S-3 - Edgar
10/27/2004 (06:02 ET) Exelixis Files Universal Shelf Registration Statement - PR Newswire
10/26/2004 (16:18 ET) EXEL: Short Interest DN 4.8% to 3.6M in Oct 2004 - Knobias
JS200
10/27/2004 (08:12 ET) EXEL: Files $200M Universal Shelf Registration - Knobias
10/27/2004 (06:07 ET) EXEL: Filed New Form S-3 - Edgar
10/27/2004 (06:02 ET) Exelixis Files Universal Shelf Registration Statement - PR Newswire
10/26/2004 (16:18 ET) EXEL: Short Interest DN 4.8% to 3.6M in Oct 2004 - Knobias
JS200
11/12/2004 (16:22 ET) EXEL: Jumps +0.77%; Vol +82%; Last 90 Min of Trading - Knobias
11/12/2004 (08:15 ET) StreetInsider Alert for EXEL - Street Insider
11/12/2004 (06:53 ET) EXEL: Wachovia Starts @ Outperform - Knobias
11/09/2004 (12:57 ET) EXEL: Goldman Sachs Keeps @ In-Line; Analyst Notes - Knobias
11/09/2004 (10:16 ET) EXEL: JP Morgan Keeps @ Neutral; Analyst Notes - Knobias
11/12/2004 (08:15 ET) StreetInsider Alert for EXEL - Street Insider
11/12/2004 (06:53 ET) EXEL: Wachovia Starts @ Outperform - Knobias
11/09/2004 (12:57 ET) EXEL: Goldman Sachs Keeps @ In-Line; Analyst Notes - Knobias
11/09/2004 (10:16 ET) EXEL: JP Morgan Keeps @ Neutral; Analyst Notes - Knobias
11/18/2004 (12:15 ET) EXEL: New Form 4 Filed, Change in Beneficial Ownership - Knobias
11/16/2004 (14:26 ET) EXEL: New Form 4 Filed, Change in Beneficial Ownership - Knobias
11/12/2004 (16:22 ET) EXEL: Jumps +0.77%; Vol +82%; Last 90 Min of Trading - Knobias
11/12/2004 (08:15 ET) StreetInsider Alert for EXEL - Street Insider
11/12/2004 (06:53 ET) EXEL: Wachovia Starts @ Outperform - Knobias
11/16/2004 (14:26 ET) EXEL: New Form 4 Filed, Change in Beneficial Ownership - Knobias
11/12/2004 (16:22 ET) EXEL: Jumps +0.77%; Vol +82%; Last 90 Min of Trading - Knobias
11/12/2004 (08:15 ET) StreetInsider Alert for EXEL - Street Insider
11/12/2004 (06:53 ET) EXEL: Wachovia Starts @ Outperform - Knobias
Schon jemand gelesen?
DGAP-News: Artemis Pharmaceuticals <DGAP> deutsch
Artemis Pharmaceuticals und Schering AG unterzeichnen Kooperationsvertrag...
Corporate-News verarbeitet und übermittelt durch die DGAP
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
--------------------------------------------------------------------------------
PRESSEMITTEILUNG 29. November 2004
Artemis Pharmaceuticals und Schering AG unterzeichnen Kooperationsvertrag
für Mausgenetik
Köln, Berlin 29. November 2004 ------- Die Artemis Pharmaceuticals GmbH (Köln)
und die Schering AG (Berlin) gaben heute den Abschluss einer
Kooperationsvereinbarung auf den Gebieten Mausgenetik und -genomik bekannt.
Im Rahmen der Forschungskooperation wird Artemis für Schering unterschiedliche
genetisch modifizierte Mausmodelle generieren. Diese werden in der
Arzneimittelforschung bei Schering dazu verwendet, für verschiedene
Krankheitsbereiche neuartige Wirkstoffe und Therapiemethoden zur Behandlung
schwerer Erkrankungen des Menschen aufzufinden und zu entwickeln. Basis für
die Züchtung der Mausmodelle, die spezifische, für die Pharmaforschung
wichtige genetische Eigenschaften aufweisen, sind die von Artemis entwickelten
ArteMiceTM und ArteMiceTMConditionalTM-Technologien. Sie ermöglichen eine
äußerst effiziente, schnelle und reproduzierbare Erzeugung von Mausmodellen
für die Wirkstofforschung, z.B. für Funktionsanalysen von Genen, die eine
zentrale Rolle im Zusammenhang mit schweren Erkrankungen spielen.
Finanzielle Einzelheiten haben die Vertragspartner im Zusammenhang mit der
Unterzeichnung der Verträge nicht bekannt gegeben.
"Wir freuen uns ganz besonders über die zukünftige Zusammenarbeit mit
Schering, einem der weltweit bedeutenden Unternehmen der Arzneimittelbranche.
Sie ist wissenschaftlich und wirtschaftlich wichtig für uns", sagte Professor
Peter Stadler, Geschäftsführer von Artemis. "Die Tatsache, dass wir nun auch
die Schering AG als neuen Kooperationspartner gewonnen haben, zeigt, dass
unsere Kunden aus der pharmazeutischen und der Biotech-Industrie den
signifikanten Wert unserer Technologieplattform zu schätzen wissen und sie für
ihre eigene Arzneimittelforschung zur Erhöhung der Forschungseffizienz
inzwischen häufig durch Kooperationen mit uns auch konkret nutzen."
Artemis Pharmaceuticals
Die Artemis Pharmaceuticals GmbH nutzt Mäuse als genetische Modellorganismen
für das Auffinden neuer Arzneimittelwirkstoffe für die Humanmedizin. Artemis
hat eine sehr leistungsfähige Technologiebasis entwickelt, die für die
Identifizierung und funktionale Validierung von Genen, die eine zentrale Rolle
im Zusammenhang mit schweren Erkrankungen des Menschen spielen, von erheblicher
Bedeutung ist. Mit der ArteMiceTM SPEED Technologie ist das Unternehmen in der
Mausgenetik führend hinsichtlich Effizienz und Minimierung des Zeitbedarfs.
Mit Hilfe der ArteMiceTM Methoden können einzelne Gene in der Maus vollständig
durch deren Humanorthologe ausgetauscht werden. Die Biologie dieser
"humanisierten" Mäuse ähnelt in besonderem Maße der des Menschen. Derartig
veränderte Mäuse können daher sehr günstig in der Arzneimittelforschung zum
frühzeitigen Testen von Wirksamkeit und Verträglichkeit neuer
Arzneimittelwirkstoffe eingesetzt werden. In Kombination mit shRNAi eröffnet
die ArteMiceTM -Technologie einen besonders effizienten Weg, gezielt Gene in
vivo in allen Geweben abzuschalten.
Zu den weiteren Kooperationspartnern von Artemis gehören Merck, Inc., Bayer,
Sanofi-Aventis, Biovitrum AB, Boehringer Ingelheim, Evotec Neurosciences,
Regeneron Pharmaceuticals, Acceleron Pharma, Benitec, Exelixis, das Deutsche
Krebsforschungszentrum u.a..
Artemis ist eine Tochtergesellschaft der Exelixis, Inc., South San Francisco,
USA.
(Nasdaq:EXEL)
Kontaktperson für weitere Auskünfte:
Artemis Pharmaceuticals GmbH
Monika Hahn
Neurather Ring 1
51063 Köln
GERMANY
Tel: +49(0)221-96453-10
Fax: +49(0)221-96453-21
m.hahn@artemispharma.de
http://www.artemispharma.de
Ende der Mitteilung, (c)DGAP 29.11.2004
--------------------------------------------------------------------------------
WKN: ; ISIN: XF000DGAP009; Index:
Notiert:
DGAP-News: Artemis Pharmaceuticals <DGAP> deutsch
Artemis Pharmaceuticals und Schering AG unterzeichnen Kooperationsvertrag...
Corporate-News verarbeitet und übermittelt durch die DGAP
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
--------------------------------------------------------------------------------
PRESSEMITTEILUNG 29. November 2004
Artemis Pharmaceuticals und Schering AG unterzeichnen Kooperationsvertrag
für Mausgenetik
Köln, Berlin 29. November 2004 ------- Die Artemis Pharmaceuticals GmbH (Köln)
und die Schering AG (Berlin) gaben heute den Abschluss einer
Kooperationsvereinbarung auf den Gebieten Mausgenetik und -genomik bekannt.
Im Rahmen der Forschungskooperation wird Artemis für Schering unterschiedliche
genetisch modifizierte Mausmodelle generieren. Diese werden in der
Arzneimittelforschung bei Schering dazu verwendet, für verschiedene
Krankheitsbereiche neuartige Wirkstoffe und Therapiemethoden zur Behandlung
schwerer Erkrankungen des Menschen aufzufinden und zu entwickeln. Basis für
die Züchtung der Mausmodelle, die spezifische, für die Pharmaforschung
wichtige genetische Eigenschaften aufweisen, sind die von Artemis entwickelten
ArteMiceTM und ArteMiceTMConditionalTM-Technologien. Sie ermöglichen eine
äußerst effiziente, schnelle und reproduzierbare Erzeugung von Mausmodellen
für die Wirkstofforschung, z.B. für Funktionsanalysen von Genen, die eine
zentrale Rolle im Zusammenhang mit schweren Erkrankungen spielen.
Finanzielle Einzelheiten haben die Vertragspartner im Zusammenhang mit der
Unterzeichnung der Verträge nicht bekannt gegeben.
"Wir freuen uns ganz besonders über die zukünftige Zusammenarbeit mit
Schering, einem der weltweit bedeutenden Unternehmen der Arzneimittelbranche.
Sie ist wissenschaftlich und wirtschaftlich wichtig für uns", sagte Professor
Peter Stadler, Geschäftsführer von Artemis. "Die Tatsache, dass wir nun auch
die Schering AG als neuen Kooperationspartner gewonnen haben, zeigt, dass
unsere Kunden aus der pharmazeutischen und der Biotech-Industrie den
signifikanten Wert unserer Technologieplattform zu schätzen wissen und sie für
ihre eigene Arzneimittelforschung zur Erhöhung der Forschungseffizienz
inzwischen häufig durch Kooperationen mit uns auch konkret nutzen."
Artemis Pharmaceuticals
Die Artemis Pharmaceuticals GmbH nutzt Mäuse als genetische Modellorganismen
für das Auffinden neuer Arzneimittelwirkstoffe für die Humanmedizin. Artemis
hat eine sehr leistungsfähige Technologiebasis entwickelt, die für die
Identifizierung und funktionale Validierung von Genen, die eine zentrale Rolle
im Zusammenhang mit schweren Erkrankungen des Menschen spielen, von erheblicher
Bedeutung ist. Mit der ArteMiceTM SPEED Technologie ist das Unternehmen in der
Mausgenetik führend hinsichtlich Effizienz und Minimierung des Zeitbedarfs.
Mit Hilfe der ArteMiceTM Methoden können einzelne Gene in der Maus vollständig
durch deren Humanorthologe ausgetauscht werden. Die Biologie dieser
"humanisierten" Mäuse ähnelt in besonderem Maße der des Menschen. Derartig
veränderte Mäuse können daher sehr günstig in der Arzneimittelforschung zum
frühzeitigen Testen von Wirksamkeit und Verträglichkeit neuer
Arzneimittelwirkstoffe eingesetzt werden. In Kombination mit shRNAi eröffnet
die ArteMiceTM -Technologie einen besonders effizienten Weg, gezielt Gene in
vivo in allen Geweben abzuschalten.
Zu den weiteren Kooperationspartnern von Artemis gehören Merck, Inc., Bayer,
Sanofi-Aventis, Biovitrum AB, Boehringer Ingelheim, Evotec Neurosciences,
Regeneron Pharmaceuticals, Acceleron Pharma, Benitec, Exelixis, das Deutsche
Krebsforschungszentrum u.a..
Artemis ist eine Tochtergesellschaft der Exelixis, Inc., South San Francisco,
USA.
(Nasdaq:EXEL)
Kontaktperson für weitere Auskünfte:
Artemis Pharmaceuticals GmbH
Monika Hahn
Neurather Ring 1
51063 Köln
GERMANY
Tel: +49(0)221-96453-10
Fax: +49(0)221-96453-21
m.hahn@artemispharma.de
http://www.artemispharma.de
Ende der Mitteilung, (c)DGAP 29.11.2004
--------------------------------------------------------------------------------
WKN: ; ISIN: XF000DGAP009; Index:
Notiert:
Anlässlich eines Artikels zu "Exelixis" (unter www.fool.com) - wie sind eure Einschätzungen, lohnt der Einstieg zum jetzigen Zeitpunkt ?
The Future of Cancer Therapy
By Charly Travers (TMF Breaker Charly)
May 10, 2005
Let me toss out a question to all of the biotech investors out there: If you had to name the most promising small biotech company working on cancer therapies, which one would top your list?
Would you go with a high-profile antibody company like Abgenix (Nasdaq: ABGX) or Medarex (Nasdaq: MEDX)? Or would you favor Celgene (Nasdaq: CELG) and Onyx Pharmaceuticals (Nasdaq: ONXX), firms with late-stage small-molecule drugs that look to be winners? What about riskier -- but potentially groundbreaking -- companies such as Cell Genesys (Nasdaq: CEGE) and Dendreon (Nasdaq: DNDN), which are leaders in developing cancer vaccines?
All of these well-known companies have had some success in clinical trials and are on the path to commercializing a product. In that light, they are all fine companies. But I think the most exciting small company discovering cancer drugs is -- hands-down -- Exelixis (Nasdaq: EXEL).
That probably puts me in the minority, since Exelixis has yet to attract the kind of attention the others regularly receive. Though it lacks name recognition, Exelixis has what could turn out to be the best drug pipeline of the bunch. And considering the exclusive company, that`s saying a lot.
Broad drug pipeline
Exelixis has an early-stage pipeline with only a single drug, XL119, in phase 3 trials. The remainder of its drugs are currently in phase 1 trials or the late preclinical research stage. So why do I think it could have the best pipeline, given its immature portfolio?
For starters, the company has been highly productive with its R&D efforts. It will have a total of eight different drugs in clinical trials by the end of 2005. On top of that, another two promising drugs will enter trials next year. That`s quite a deep bench.
With so many programs moving forward, Exelixis` success is not highly dependent upon a single drug program. That`s a stark contrast to many of its peers, which will sink or swim on the fate of a single product. Exelixis can potentially absorb a few of the inevitable failures of clinical trials and still have enough drugs in the works to become a successful company.
Having a significant number of drugs in clinical trials increases a company`s "shots on goal." But it`s not just the quantity that has caught my eye; it`s the targets that these drugs are hitting.
High-quality targets
Let me step back for a second. The dominant trend in cancer-drug development over the past few years has been to inhibit receptors or enzymes known to be involved in the growth of tumor cells. The idea is that shutting these down will stop the cancer from growing. It`s like taking a piece of gum and plugging up the ignition switch of your car so that you can`t stick the key in and start it up.
Many of Exelixis` drugs hit important targets in the regulation of cancer-cell growth. These include receptors such as VEGF, EGF, and HER2, as well as enzymes like Raf and Akt.
Investors who follow cancer companies will recognize those targets -- some of the most prominent cancer drugs on today`s market hit the exact same ones. Avastin, Herceptin, Erbitux, and Tarceva are all approved drugs that work through these pathways.
The presence of already-approved products that work by inhibiting these receptors validates that the drug development strategy is sound. Significant risk is reduced because we`re not left wondering whether the company`s targets are even relevant to the treatment of cancer -- we already know they are.
The Foolish bottom line
I`ll go out on a limb and say that in two years Exelixis will be an important player in the development of cancer drugs. I set my time frame at two years because it will take some time for the pipeline to mature a bit and generate preliminary clinical data that will suggest whether or not some of the drugs work.
Of particular importance here are XL119, XL647, and XL999. XL119 is currently in a phase 3 trial for bile duct tumors. XL674 and XL999 are both slated to enter phase 2 trials later this year.
With that in mind, and looking forward a bit, we`ll need to pay particular attention to the American Society of Clinical Oncology (ASCO) meeting in the summer of 2007. The annual ASCO meeting is the most important cancer meeting every year, and it is where developmental drugs are put on display. Given the timelines for the most advanced drugs in Exelixis` portfolio, by that meeting we should know how the drugs are doing and whether they will be successful.
The Future of Cancer Therapy
By Charly Travers (TMF Breaker Charly)
May 10, 2005
Let me toss out a question to all of the biotech investors out there: If you had to name the most promising small biotech company working on cancer therapies, which one would top your list?
Would you go with a high-profile antibody company like Abgenix (Nasdaq: ABGX) or Medarex (Nasdaq: MEDX)? Or would you favor Celgene (Nasdaq: CELG) and Onyx Pharmaceuticals (Nasdaq: ONXX), firms with late-stage small-molecule drugs that look to be winners? What about riskier -- but potentially groundbreaking -- companies such as Cell Genesys (Nasdaq: CEGE) and Dendreon (Nasdaq: DNDN), which are leaders in developing cancer vaccines?
All of these well-known companies have had some success in clinical trials and are on the path to commercializing a product. In that light, they are all fine companies. But I think the most exciting small company discovering cancer drugs is -- hands-down -- Exelixis (Nasdaq: EXEL).
That probably puts me in the minority, since Exelixis has yet to attract the kind of attention the others regularly receive. Though it lacks name recognition, Exelixis has what could turn out to be the best drug pipeline of the bunch. And considering the exclusive company, that`s saying a lot.
Broad drug pipeline
Exelixis has an early-stage pipeline with only a single drug, XL119, in phase 3 trials. The remainder of its drugs are currently in phase 1 trials or the late preclinical research stage. So why do I think it could have the best pipeline, given its immature portfolio?
For starters, the company has been highly productive with its R&D efforts. It will have a total of eight different drugs in clinical trials by the end of 2005. On top of that, another two promising drugs will enter trials next year. That`s quite a deep bench.
With so many programs moving forward, Exelixis` success is not highly dependent upon a single drug program. That`s a stark contrast to many of its peers, which will sink or swim on the fate of a single product. Exelixis can potentially absorb a few of the inevitable failures of clinical trials and still have enough drugs in the works to become a successful company.
Having a significant number of drugs in clinical trials increases a company`s "shots on goal." But it`s not just the quantity that has caught my eye; it`s the targets that these drugs are hitting.
High-quality targets
Let me step back for a second. The dominant trend in cancer-drug development over the past few years has been to inhibit receptors or enzymes known to be involved in the growth of tumor cells. The idea is that shutting these down will stop the cancer from growing. It`s like taking a piece of gum and plugging up the ignition switch of your car so that you can`t stick the key in and start it up.
Many of Exelixis` drugs hit important targets in the regulation of cancer-cell growth. These include receptors such as VEGF, EGF, and HER2, as well as enzymes like Raf and Akt.
Investors who follow cancer companies will recognize those targets -- some of the most prominent cancer drugs on today`s market hit the exact same ones. Avastin, Herceptin, Erbitux, and Tarceva are all approved drugs that work through these pathways.
The presence of already-approved products that work by inhibiting these receptors validates that the drug development strategy is sound. Significant risk is reduced because we`re not left wondering whether the company`s targets are even relevant to the treatment of cancer -- we already know they are.
The Foolish bottom line
I`ll go out on a limb and say that in two years Exelixis will be an important player in the development of cancer drugs. I set my time frame at two years because it will take some time for the pipeline to mature a bit and generate preliminary clinical data that will suggest whether or not some of the drugs work.
Of particular importance here are XL119, XL647, and XL999. XL119 is currently in a phase 3 trial for bile duct tumors. XL674 and XL999 are both slated to enter phase 2 trials later this year.
With that in mind, and looking forward a bit, we`ll need to pay particular attention to the American Society of Clinical Oncology (ASCO) meeting in the summer of 2007. The annual ASCO meeting is the most important cancer meeting every year, and it is where developmental drugs are put on display. Given the timelines for the most advanced drugs in Exelixis` portfolio, by that meeting we should know how the drugs are doing and whether they will be successful.
Heute im "Aktionär"
Exelixis initiates early stage trial of anti-cancer drug
Exelixis has initiated a phase I clinical trial to evaluate the safety, tolerability and bodily reaction to XL820, an orally administered, anti-cancer compound. The trial will be conducted in patients with solid tumors for whom there are no available therapies known to prolong survival.
26 Jul 2005, 17:07 GMT - The company has been encouraged to initiate the clinical phase of development by positive results in preclinical studies. XL820 has exhibited dose-dependent growth inhibition in models of breast carcinoma, gliomas and leukemia. Also, in an animal model of more advanced malignancy, significant tumor regression was seen.
"This is the second of four compounds we expect to enter into phase I clinical trials this year. I am incredibly proud of the diligent work of our clinical development team. Their extraordinary ability to execute is essential to the success of Exelixis as we move towards reaching the goal of providing novel therapies to cancer patients," said Dr George Scangos, president and CEO of Exelixis.
The trial will be conducted at two highly regarded centers, one being the CTRC (Cancer Therapy and Research Center) Institute for Drug Development (IDD) in San Antonio, Texas.
Source: Datamonitor Newswire
Exelixis has initiated a phase I clinical trial to evaluate the safety, tolerability and bodily reaction to XL820, an orally administered, anti-cancer compound. The trial will be conducted in patients with solid tumors for whom there are no available therapies known to prolong survival.
26 Jul 2005, 17:07 GMT - The company has been encouraged to initiate the clinical phase of development by positive results in preclinical studies. XL820 has exhibited dose-dependent growth inhibition in models of breast carcinoma, gliomas and leukemia. Also, in an animal model of more advanced malignancy, significant tumor regression was seen.
"This is the second of four compounds we expect to enter into phase I clinical trials this year. I am incredibly proud of the diligent work of our clinical development team. Their extraordinary ability to execute is essential to the success of Exelixis as we move towards reaching the goal of providing novel therapies to cancer patients," said Dr George Scangos, president and CEO of Exelixis.
The trial will be conducted at two highly regarded centers, one being the CTRC (Cancer Therapy and Research Center) Institute for Drug Development (IDD) in San Antonio, Texas.
Source: Datamonitor Newswire
EXELIXIS , immer weiter gehts Richtung Norden... und keiner honoriert es hier 
Die Besondere unter vielen
Bis ein Patient ein wirksames, neues Medikament in der Hand hat, dauert es lange.
Aktien von Unternehmen, die Mittel gegen Krebs entwickeln, sind en vogue. Die kleine US-Firma Exelixis hat aber bisher kaum jemand auf dem Zettel.
Von Frank Philips
Aktien von Unternehmen, die neuartige Medikamente gegen Krebs entwickeln, sind derzeit bei den Anlegern gefragt. Zum einen mag dies dem so genannten "ASCO-Effekt" geschuldet sein. Das jährliche Treffen der Krebsspezialisten, das in der letzten Woche in Orlando/Florida stattfand, strahlte einmal mehr bereits im Vorfeld etwas von seinem Glanz auf die gesamte Branche ab. Aktien von Firmen wie Genentech oder Celgene stiegen bereits im Vorfeld der Konferenz. Weniger bekannt, aber deswegen nicht weniger interessant, ist das Papier von Exelixis. Denn die Firma aus South San Francisco ist ein echtes Kleinod.
Pralle Pipeline
Der Exelixis-Jahreschart
Was Exelixis vor anderen Unternehmen der gleichen Couleur auszeichnet, ist die starke Pipeline. Insgesamt fünf Produktkandidaten durchlaufen derzeit klinische Studien, drei weitere sollen noch in diesem Jahr folgen. Die hohe Anzahl der Produktkandidaten verringert die Abhängigkeit von nur einem Wirkstoff und gibt sowohl dem Unternehmen als auch dem Anleger eine gewisse Sicherheit. Der am weitesten fortgeschrittene Wirkstoff von Exelixis ist ein potenzielles Mittel zur Behandlung von Gallengangkrebs. Zur Therapie dieser extrem bösartigen Krebsart stehen den Medizinern bislang kaum schlagkräftige medikamentöse Optionen offen. Dies könnte sich in zwei bis drei Jahren ändern, wenn sich die bisher gezeigten Resultate mit dem von Exelixis entwickelten Wirkstoff XL 119 in den Phase-III-Studien, die derzeit durchgeführt werden, bestätigen. Die vier übrigen Produktkandidaten befinden sich aktuell noch in der ersten Phase der klinischen Studien. Zumindest bei zweien, mit denen unter anderem das Tumorwachstum bei Brust-, Lungen- und Darmkrebs gebremst werden soll, werden noch in diesem Jahr aussagekräftige Ergebnisse erwartet. Dann könnten bereits Phase-II-Tests beginnen.
Starker Partner
Finanziell ist die weitere Entwicklung zunächst einmal gesichert. Allein mit den liquiden Mitteln von über 170 Millionen Dollar kann Exelixis sich mindestens bis Ende 2006 über Wasser halten. Frisches Geld erhält das Unternehmen darüber hinaus aus der Partnerschaft mit dem Pharmakonzern GlaxoSmithKline, der erst vor kurzem 35 Millionen Dollar an Exelixis überwies. Insgesamt könnten Exelixis - eine weiterhin erfolgreiche Entwicklung der Krebsmedikamente vorausgesetzt - weitere Zahlungen in Höhe von bis zu 350 Millionen Dollar zufließen.
Kaufen!
Die Aktie von Exelixis ist auf dem aktuellen Niveau ein klarer Kauf für langfristig orientierte Anleger. Die Firma könnte in einigen Jahren zur Crème de la Crème der Entwickler von Krebsmedikamenten gehören. Vor diesem Hintergrund kann es nicht schaden, sich bereits jetzt einige Stücke als Beimischung ins Depot zu packen.
Die Voraussetzungen sind bestens
Exelixis
ISIN US30161Q1040
Kurs am 24.05.2005 5,97€
Empfehlungskurs 4,50€
Ziel 9,00€
Stopp 3,50€
KGV 06e --
Chance/Risiko 5/4
Artikel aus DER AKTIONÄR (21/05).
Bis ein Patient ein wirksames, neues Medikament in der Hand hat, dauert es lange.
Aktien von Unternehmen, die Mittel gegen Krebs entwickeln, sind en vogue. Die kleine US-Firma Exelixis hat aber bisher kaum jemand auf dem Zettel.
Von Frank Philips
Aktien von Unternehmen, die neuartige Medikamente gegen Krebs entwickeln, sind derzeit bei den Anlegern gefragt. Zum einen mag dies dem so genannten "ASCO-Effekt" geschuldet sein. Das jährliche Treffen der Krebsspezialisten, das in der letzten Woche in Orlando/Florida stattfand, strahlte einmal mehr bereits im Vorfeld etwas von seinem Glanz auf die gesamte Branche ab. Aktien von Firmen wie Genentech oder Celgene stiegen bereits im Vorfeld der Konferenz. Weniger bekannt, aber deswegen nicht weniger interessant, ist das Papier von Exelixis. Denn die Firma aus South San Francisco ist ein echtes Kleinod.
Pralle Pipeline
Der Exelixis-Jahreschart
Was Exelixis vor anderen Unternehmen der gleichen Couleur auszeichnet, ist die starke Pipeline. Insgesamt fünf Produktkandidaten durchlaufen derzeit klinische Studien, drei weitere sollen noch in diesem Jahr folgen. Die hohe Anzahl der Produktkandidaten verringert die Abhängigkeit von nur einem Wirkstoff und gibt sowohl dem Unternehmen als auch dem Anleger eine gewisse Sicherheit. Der am weitesten fortgeschrittene Wirkstoff von Exelixis ist ein potenzielles Mittel zur Behandlung von Gallengangkrebs. Zur Therapie dieser extrem bösartigen Krebsart stehen den Medizinern bislang kaum schlagkräftige medikamentöse Optionen offen. Dies könnte sich in zwei bis drei Jahren ändern, wenn sich die bisher gezeigten Resultate mit dem von Exelixis entwickelten Wirkstoff XL 119 in den Phase-III-Studien, die derzeit durchgeführt werden, bestätigen. Die vier übrigen Produktkandidaten befinden sich aktuell noch in der ersten Phase der klinischen Studien. Zumindest bei zweien, mit denen unter anderem das Tumorwachstum bei Brust-, Lungen- und Darmkrebs gebremst werden soll, werden noch in diesem Jahr aussagekräftige Ergebnisse erwartet. Dann könnten bereits Phase-II-Tests beginnen.
Starker Partner
Finanziell ist die weitere Entwicklung zunächst einmal gesichert. Allein mit den liquiden Mitteln von über 170 Millionen Dollar kann Exelixis sich mindestens bis Ende 2006 über Wasser halten. Frisches Geld erhält das Unternehmen darüber hinaus aus der Partnerschaft mit dem Pharmakonzern GlaxoSmithKline, der erst vor kurzem 35 Millionen Dollar an Exelixis überwies. Insgesamt könnten Exelixis - eine weiterhin erfolgreiche Entwicklung der Krebsmedikamente vorausgesetzt - weitere Zahlungen in Höhe von bis zu 350 Millionen Dollar zufließen.
Kaufen!
Die Aktie von Exelixis ist auf dem aktuellen Niveau ein klarer Kauf für langfristig orientierte Anleger. Die Firma könnte in einigen Jahren zur Crème de la Crème der Entwickler von Krebsmedikamenten gehören. Vor diesem Hintergrund kann es nicht schaden, sich bereits jetzt einige Stücke als Beimischung ins Depot zu packen.
Die Voraussetzungen sind bestens
Exelixis
ISIN US30161Q1040
Kurs am 24.05.2005 5,97€
Empfehlungskurs 4,50€
Ziel 9,00€
Stopp 3,50€
KGV 06e --
Chance/Risiko 5/4
Artikel aus DER AKTIONÄR (21/05).
Comeback der Biotechs
Die Aktien der amerikanischen Biotechnologieunternehmen könnten im zweiten Halbjahr vom guten fundamentalen Umfeld profitieren. DER AKTIONÄR stellt Ihnen zwei aussichtsreiche Werte vor.
Von Olaf Hordenbach
Erlebt die Börse im zweiten Halbjahr ein Comeback der Biotechnologieaktien? Gut möglich, denn Tatsache ist, dass viele Biotechnologieunternehmen heute besser dastehen als je zuvor. Mit Hochdruck arbeiten sie an der Entwicklung und Markteinführung von neuen Produkten - und dies mit zunehmendem Erfolg. In den USA sind bereits 190 Biotechnologieprodukte zugelassen, über 1.000 weitere befinden sich in der klinischen Entwicklung. Biotechnologisch hergestellte Medikamente machen heute bereits 57 Prozent der neu auf den Markt gebrachten Arzneimittel aus. Mit Biotechnologie-Medikamenten erzielen die Unternehmen ansehnliche Bruttomargen und verfügen gleichzeitig über eine starke Preismacht, denn in der Regel gibt es keine Nachahmerprodukte, so genannte Generika, die den Preis drücken könnten.
Deshalb wundert es denn auch nicht, dass immer mehr Biotechnologieunternehmen den Break-even schaffen und Gewinne erwirtschaften. Von den derzeit 161 Gesellschaften, die im Nasdaq-Biotech-Index, dem wichtigsten Aktienbarometer in Sachen Biotechnologie, gelistet sind, werden schätzungsweise 59 im kommenden Jahr schwarze Zahlen schreiben.
Zwei Unternehmen, die für das zweite Halbjahr 2005 noch gutes Kurspotenzial versprechen, sind OSI Pharmaceuticals und Exelixis.
OSI Pharmaceuticals - schwarze Zahlen ab 2007
Das amerikanische Unternehmen OSI Pharmaceuticals hat sich auf die Bereiche Krebstherapie und Diabetesbehandlung spezialisiert. Wichtigstes Medikament in der Produktpalette von OSI ist das Krebspräparat Tarceva, das bereits erfolgreich vermarktet wird. OSI arbeitet zudem eng mit dem US-Konzern Genentech und der Schweizer Pharmagesellschaft Roche zusammen.
Hohe Entwicklungs- und Forschungskosten dürften jedoch dazu führen, dass OSI 2005 und 2006 Verluste einfahren wird. Für 2007 wird dann allerdings mit einem Gewinn je Anteilschein von 1,19 Dollar der Break-even erwartet.
OSI Pharmaceuticals
ISIN US6710401034
Kurs am 03.08.2005 33,53€
Empfehlungskurs 38,80€
Ziel 50,00€
Stopp 28,00€
KGV 06e -
Chance/Risiko 3/2
Exelixis - vielversprechende Produktpipeline gegen Krebs
Die kleine US-Biotech-Firma Exelixis aus South San Francisco in Kalifornien hat derzeit kaum ein Anleger auf dem Zettel. Zu Unrecht, denn Exelixis verfügt über eine mehr als vielversprechende Produktpipeline. Insgesamt fünf experimentelle Wirkstoffe zur Behandlung verschiedener Krebsarten befinden sich aktuell in unterschiedlichen Phasen der klinischen Entwicklung.
Am weitesten fortgeschritten ist dabei ein Produktkandidat mit der Bezeichnung XL 119. Die Arznei soll zur Behandlung von Gallengangkrebs eingesetzt werden. Gegen die bösartige Krebsart stehen Medizinern bislang kaum Therapieoptionen zur Verfügung. Sollten sich die Resultate, die Exelixis in den bisherigen Studien mit XL 119 erzielt hat, bestätigen, könnte sich dies auf Sicht von zwei bis drei Jahren ändern. Für Exelixis wäre dies gleichzeitig die erste Produktzulassung.
Exelixis
ISIN US30161Q1040
Kurs am 03.08.2005 7,59€
Empfehlungskurs 7,40€
Ziel 15,00€
Stopp 5,90€
KGV 06e -
Chance/Risiko 5/4
Gutes Potenzial
Die Biotechnologieaktien bieten im zweiten Halbjahr 2005 unter fundamentalen und charttechnischen (siehe Kasten links) Gesichtspunkten gutes Aufwärtspotenzial. Um dieses auszunutzen, können Anleger auf OSI Pharmaceuticals und Exelixis setzen. Exelixis ist dabei die spekulativere Variante, die sich nur für eine kleinere Depotbeimischung eignet. OSI kann dagegen in einem Portfolio höher gewichtet werden.
Artikel aus DER AKTIONÄR (31/05).
Die Aktien der amerikanischen Biotechnologieunternehmen könnten im zweiten Halbjahr vom guten fundamentalen Umfeld profitieren. DER AKTIONÄR stellt Ihnen zwei aussichtsreiche Werte vor.
Von Olaf Hordenbach
Erlebt die Börse im zweiten Halbjahr ein Comeback der Biotechnologieaktien? Gut möglich, denn Tatsache ist, dass viele Biotechnologieunternehmen heute besser dastehen als je zuvor. Mit Hochdruck arbeiten sie an der Entwicklung und Markteinführung von neuen Produkten - und dies mit zunehmendem Erfolg. In den USA sind bereits 190 Biotechnologieprodukte zugelassen, über 1.000 weitere befinden sich in der klinischen Entwicklung. Biotechnologisch hergestellte Medikamente machen heute bereits 57 Prozent der neu auf den Markt gebrachten Arzneimittel aus. Mit Biotechnologie-Medikamenten erzielen die Unternehmen ansehnliche Bruttomargen und verfügen gleichzeitig über eine starke Preismacht, denn in der Regel gibt es keine Nachahmerprodukte, so genannte Generika, die den Preis drücken könnten.
Deshalb wundert es denn auch nicht, dass immer mehr Biotechnologieunternehmen den Break-even schaffen und Gewinne erwirtschaften. Von den derzeit 161 Gesellschaften, die im Nasdaq-Biotech-Index, dem wichtigsten Aktienbarometer in Sachen Biotechnologie, gelistet sind, werden schätzungsweise 59 im kommenden Jahr schwarze Zahlen schreiben.
Zwei Unternehmen, die für das zweite Halbjahr 2005 noch gutes Kurspotenzial versprechen, sind OSI Pharmaceuticals und Exelixis.
OSI Pharmaceuticals - schwarze Zahlen ab 2007
Das amerikanische Unternehmen OSI Pharmaceuticals hat sich auf die Bereiche Krebstherapie und Diabetesbehandlung spezialisiert. Wichtigstes Medikament in der Produktpalette von OSI ist das Krebspräparat Tarceva, das bereits erfolgreich vermarktet wird. OSI arbeitet zudem eng mit dem US-Konzern Genentech und der Schweizer Pharmagesellschaft Roche zusammen.
Hohe Entwicklungs- und Forschungskosten dürften jedoch dazu führen, dass OSI 2005 und 2006 Verluste einfahren wird. Für 2007 wird dann allerdings mit einem Gewinn je Anteilschein von 1,19 Dollar der Break-even erwartet.
OSI Pharmaceuticals
ISIN US6710401034
Kurs am 03.08.2005 33,53€
Empfehlungskurs 38,80€
Ziel 50,00€
Stopp 28,00€
KGV 06e -
Chance/Risiko 3/2
Exelixis - vielversprechende Produktpipeline gegen Krebs
Die kleine US-Biotech-Firma Exelixis aus South San Francisco in Kalifornien hat derzeit kaum ein Anleger auf dem Zettel. Zu Unrecht, denn Exelixis verfügt über eine mehr als vielversprechende Produktpipeline. Insgesamt fünf experimentelle Wirkstoffe zur Behandlung verschiedener Krebsarten befinden sich aktuell in unterschiedlichen Phasen der klinischen Entwicklung.
Am weitesten fortgeschritten ist dabei ein Produktkandidat mit der Bezeichnung XL 119. Die Arznei soll zur Behandlung von Gallengangkrebs eingesetzt werden. Gegen die bösartige Krebsart stehen Medizinern bislang kaum Therapieoptionen zur Verfügung. Sollten sich die Resultate, die Exelixis in den bisherigen Studien mit XL 119 erzielt hat, bestätigen, könnte sich dies auf Sicht von zwei bis drei Jahren ändern. Für Exelixis wäre dies gleichzeitig die erste Produktzulassung.
Exelixis
ISIN US30161Q1040
Kurs am 03.08.2005 7,59€
Empfehlungskurs 7,40€
Ziel 15,00€
Stopp 5,90€
KGV 06e -
Chance/Risiko 5/4
Gutes Potenzial
Die Biotechnologieaktien bieten im zweiten Halbjahr 2005 unter fundamentalen und charttechnischen (siehe Kasten links) Gesichtspunkten gutes Aufwärtspotenzial. Um dieses auszunutzen, können Anleger auf OSI Pharmaceuticals und Exelixis setzen. Exelixis ist dabei die spekulativere Variante, die sich nur für eine kleinere Depotbeimischung eignet. OSI kann dagegen in einem Portfolio höher gewichtet werden.
Artikel aus DER AKTIONÄR (31/05).
Kann mir das mal einer übersetzen und dann sagen warum die Aktie fällt ?http://www.finanznachrichten.de/nachrichten-2005-08/artikel-…
09/22/2005 (06:00 ET) Exelixis Starts Three New Phase I Clinical Trials for Novel Compounds XL844, XL184 and XL784 - PR Newswire
09/21/2005 (16:32 ET) EXEL: To Present At Bank of America Conference @ 18:30 ET - Knobias
09/20/2005 (16:22 ET) EXEL: Drops -2.39%; Vol +117%; Last 90 Min of Trading - Knobias
09/15/2005 (16:00 ET) Exelixis Announces September 21 Webcast of Presentation at the Bank of America 35th Annual Investment Conference - PR Newswire
09/12/2005 (08:02 ET) EXEL: To Present At Bear Stearns Conference @ 10:00 ET - Knobias
09/21/2005 (16:32 ET) EXEL: To Present At Bank of America Conference @ 18:30 ET - Knobias
09/20/2005 (16:22 ET) EXEL: Drops -2.39%; Vol +117%; Last 90 Min of Trading - Knobias
09/15/2005 (16:00 ET) Exelixis Announces September 21 Webcast of Presentation at the Bank of America 35th Annual Investment Conference - PR Newswire
09/12/2005 (08:02 ET) EXEL: To Present At Bear Stearns Conference @ 10:00 ET - Knobias
10/11/2005 (16:19 ET) EXEL: Filed New Form SC 13G, Beneficial Ownership Disclosure - Edgar
10/11/2005 (11:38 ET) /C O R R E C T I O N -- Exelixis, Inc./ - PR Newswire
10/11/2005 (06:00 ET) Data From Exelixis Phase I Clinical Trials of Xl647, Xl999 and Xl880 to Be Presented at International Conference on Molecular Targets and Cancer Therapeutics - PR Newswire
10/06/2005 (16:22 ET) EXEL: Drops -1.10%; Vol +79%; Last 90 Min of Trading - Knobias
10/06/2005 (15:09 ET) EXEL: New Form 4 Filed, Change in Beneficial Ownership - Edgar
10/11/2005 (11:38 ET) /C O R R E C T I O N -- Exelixis, Inc./ - PR Newswire
10/11/2005 (06:00 ET) Data From Exelixis Phase I Clinical Trials of Xl647, Xl999 and Xl880 to Be Presented at International Conference on Molecular Targets and Cancer Therapeutics - PR Newswire
10/06/2005 (16:22 ET) EXEL: Drops -1.10%; Vol +79%; Last 90 Min of Trading - Knobias
10/06/2005 (15:09 ET) EXEL: New Form 4 Filed, Change in Beneficial Ownership - Edgar
10/20/2005 (16:00 ET) Exelixis Announces November 3 Webcast of Its Third Quarter 2005 Financial Results Conference Call - PR Newswire
10/19/2005 (15:02 ET) EXEL: To Present At 2005 MEDIC Conference @ 17:00 ET - Knobias
10/14/2005 (16:48 ET) EXEL: Filed New Form 8-K, Material Event Disclosure - Edgar
10/13/2005 (17:21 ET) AgraQuest names R&D executive - Knight Ridder/Tribune Business News
10/13/2005 (16:21 ET) EXEL: Jumps +2.10%; Vol +69%; Last 90 Min of Trading - Knobias
10/19/2005 (15:02 ET) EXEL: To Present At 2005 MEDIC Conference @ 17:00 ET - Knobias
10/14/2005 (16:48 ET) EXEL: Filed New Form 8-K, Material Event Disclosure - Edgar
10/13/2005 (17:21 ET) AgraQuest names R&D executive - Knight Ridder/Tribune Business News
10/13/2005 (16:21 ET) EXEL: Jumps +2.10%; Vol +69%; Last 90 Min of Trading - Knobias
11/23/2005 (13:11 ET) EXEL: New Form 4 Filed, Change in Beneficial Ownership - Edgar
11/18/2005 (19:22 ET) EXEL: New Form 4 Filed, Change in Beneficial Ownership - Edgar
11/17/2005 (13:15 ET) StreetInsider Alert for EXEL - Street Insider
11/17/2005 (12:57 ET) Data From Phase I Trial of Exelixis` XL999 Establishing MTD Presented at Cancer Conference - PR Newswire
11/15/2005 (12:49 ET) Data From Phase I Trial of Exelixis` XL647 Presented at Cancer Conference - PR Newswire
11/18/2005 (19:22 ET) EXEL: New Form 4 Filed, Change in Beneficial Ownership - Edgar
11/17/2005 (13:15 ET) StreetInsider Alert for EXEL - Street Insider
11/17/2005 (12:57 ET) Data From Phase I Trial of Exelixis` XL999 Establishing MTD Presented at Cancer Conference - PR Newswire
11/15/2005 (12:49 ET) Data From Phase I Trial of Exelixis` XL647 Presented at Cancer Conference - PR Newswire
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -1,13 | |
| +11,67 | |
| +0,42 | |
| -1,61 | |
| +1,11 | |
| -0,37 | |
| -0,59 | |
| -1,22 | |
| +1,83 | |
| -0,09 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 191 | ||
| 98 | ||
| 71 | ||
| 67 | ||
| 67 | ||
| 47 | ||
| 42 | ||
| 33 | ||
| 28 | ||
| 27 |
01.04.24 · wO Chartvergleich · Consolidated Water |
29.03.24 · wO Chartvergleich · Consolidated Water |
28.03.24 · wO Chartvergleich · Energiekontor |